Management Comment "The combination of our proprietary Fc-optimized anti-HER2 antibody, with expected enhanced immune-mediated killing properties, and the anti-PD-1 antibody KEYTRUDA (pembrolizumab), is intended to exploit potentially complementary biology," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Treatment options for patients with advanced HER2-positive gastric cancer are extremely limited. The combination of mechanisms engaged by margetuximab and KEYTRUDA could provide an important alternative for patients who do not respond to currently available regimens."